Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Zhaojuan Jiang, Qingwan Li, Jinqiu Ruan, Yanli Li, Dafu Zhang, Yongzhou Xu, Yuting Liao, Xin Zhang, Depei Gao, Zhenhui Li
BACKGROUND: Neoadjuvant chemotherapy has variable efficacy in patients with non-small-cell lung cancer (NSCLC), yet reliable noninvasive predictive markers are lacking. This study aimed to develop a radiomics model predicting pathological complete response and postneoadjuvant chemotherapy survival in NSCLC. MATERIALS AND METHODS: Retrospective data collection involved 130 patients with NSCLC who underwent neoadjuvant chemotherapy and surgery. Patients were randomly divided into training and independent testing sets...
April 12, 2024: Clinical Lung Cancer
#2
JOURNAL ARTICLE
Ernest Moles, David W Chang, Friederike M Mansfeld, Alastair Duly, Kathleen Kimpton, Amy Logan, Christopher B Howard, Kristofer J Thurecht, Maria Kavallaris
INTRODUCTION: Despite improvements in chemotherapy and molecularly targeted therapies, the life expectancy of patients with advanced non-small cell lung cancer (NSCLC) remains less than 1 year. There is thus a major global need to advance new treatment strategies that are more effective for NSCLC. Drug delivery using liposomal particles has shown success at improving the biodistribution and bioavailability of chemotherapy. Nevertheless, liposomal drugs lack selectivity for the cancer cells and have a limited ability to penetrate the tumor site, which severely limits their therapeutic potential...
2024: International Journal of Nanomedicine
#3
JOURNAL ARTICLE
Melina Peressini, Rosario Garcia-Campelo, Bartomeu Massuti, Cristina Marti, Manuel Cobo, Vanesa Gutiérrez, Manuel Dómine, Jose Fuentes, Margarita Majem, Javier de Castro, Juan Felipe Cordoba, Maria Pilar Diz, Dolores Isla, Emilio Esteban, Enric Carcereny, Laia Vila, Alberto Moreno-Vega, Silverio Ros, Amaia Moreno, Francisco Javier Garcia, Gerardo Huidobro, Carlos Aguado, Victor Cebey-Lopez, Javier Valdivia, Ramon Palmero, Pilar Lianes, Marta Lopez-Brea, Oscar Juan Vidal, Mariano Provencio, Edurne Arriola, Javier Baena, Mercedes Herrera, Helena Bote, Magdalena Molero, Vera Adradas, Santiago Ponce-Aix, Angel Nuñez-Buiza, Álvaro Ucero, Susana Hernandez, Fernando Lopez-Rios, Esther Conde, Luis Paz-Ares, Jon Zugazagoitia
BACKGROUND: Transcriptomic subtyping holds promise for personalized therapy in extensive-stage small-cell lung cancer (ES-SCLC). In this study, we aimed to assess intratumoral transcriptomic subtype diversity and to identify biomarkers of long-term chemoimmunotherapy benefit in human ES-SCLC. PATIENTS AND METHODS: We analyzed tumor samples from 58 ES-SCLC patients enrolled in two multicenter single-arm phase IIIb studies evaluating front-line chemoimmunotherapy in Spain: n=32 from the IMfirst trial, and n=26 from the CANTABRICO trial...
April 17, 2024: Clinical Cancer Research
#4
JOURNAL ARTICLE
Sarah Ducellier, Mélanie Demeules, Boris Letribot, Massimiliano Gaetani, Chloé Michaudel, Harry Sokol, Abdallah Hamze, Mouad Alami, Mégane Nascimento, Sébastien Apcher
BACKGROUND: Despite the current therapeutic treatments including surgery, chemotherapy, radiotherapy and more recently immunotherapy, the mortality rate of lung cancer stays high. Regarding lung cancer, epigenetic modifications altering cell cycle, angiogenesis and programmed cancer cell death are therapeutic targets to combine with immunotherapy to improve treatment success. In a recent study, we uncovered that a molecule called QAPHA ((E)-3-(5-((2-cyanoquinolin-4-yl)(methyl)amino)-2-methoxyphenyl)-N-hydroxyacrylamide) has a dual function as both a tubulin polymerization and HDAC inhibitors...
April 11, 2024: Journal for Immunotherapy of Cancer
#5
REVIEW
Takaaki Ito
Pulmonary neuroendocrine (NE) cells are rare airway epithelial cells. The balance between Achaete-scute complex homolog 1 (ASCL1) and hairy and enhancer of split 1, one of the target molecules of the Notch signaling pathway, is crucial for NE differentiation. Small cell lung cancer (SCLC) is a highly aggressive lung tumor, characterized by rapid cell proliferation, a high metastatic potential, and the acquisition of resistance to treatment. The subtypes of SCLC are defined by the expression status of NE cell-lineage transcription factors, such as ASCL1, which roles are supported by SRY-box 2, insulinoma-associated protein 1, NK2 homeobox 1, and wingless-related integration site signaling...
April 12, 2024: Pathology International
#6
JOURNAL ARTICLE
Suzuna Sakai, Kojiro Ohba, Kazunari Migita, Ichiro Sekine, Yasuto Yamazaki
We herein report an extremely rare case of intratumoral metastasis of colon cancer to chromophobe renal cell carcinoma. A 71-year-old woman was diagnosed with lung metastasis of sigmoid colon cancer and underwent sigmoid colon resection with D3 lymph node dissection. Preoperative contrast-enhanced computed tomography (CT) revealed a left renal tumor; however, colon resection was prioritized, and the renal tumor was placed under observation. Two years later, CT revealed enlargement of the left renal tumor, and laparoscopic partial left nephrectomy was performed 1 month later...
April 2024: International cancer conference journal
#7
JOURNAL ARTICLE
Aykut Elicora, Busra Yaprak Bayrak, Cigdem Vural, Huseyin Fatih Sezer, Semra Uzun Erkal, Elif Metin
OBJECTIVE: The basis for current and future lung cancer immunotherapy depends on our knowledge of molecular mechanisms of interactions between tumor and immune system cells. Interactions that occur between different intratumoral populations of the same cells are important. In our study, we aimed to evaluate relationship between the clinical and prognostic features and T lymphocyte subgroups of patients with lung tumors after neoadjuvant treatment. METHODS: A total of 72 patients were included in our study, including study group, 39 of whom received neoadjuvant chemotherapy...
March 11, 2024: Journal of Cardiothoracic Surgery
#8
JOURNAL ARTICLE
Jianghua Wu, Wei Sun, Yanhui Zhang, Luning Mao, Tingting Ding, Xiaozheng Huang, Dongmei Lin
PURPOSE: To investigate the impact of platinum-based adjuvant chemotherapy on the immunotherapeutic biomarkers of postoperative recurrent tumors in non-small cell lung cancer (NSCLC). METHODS: This study involved twenty-two cases of NSCLC, all of which underwent postoperative platinum-based chemotherapy, with matched surgical samples obtained from both their primary tumors (PTs) and recurrent tumors (RTs). Multiplex immunofluorescence was performed to assess the tumor proportion score (TPS) and immune cells (IC) on whole sections...
February 29, 2024: Clinical & Translational Oncology
#9
JOURNAL ARTICLE
Zonghao Liu, Weikun Li, Xin Tan, Yueru Huang, Yinghua Tao, Ning Yang, Renqiang Yuan, Ling Liu, Liqin Ge
Improved techniques for the administration of chemotherapeutic drugs are required to enhance tumor therapy efficacy and reduce the side effects of chemotherapy due to insufficient targeting and limited intratumoral drug release. Controlled drug delivery systems combined with thermotherapy are expected to play an important role in personalized tumor therapy. Herein, a novel microwave-responsive transformable magnetic liquid-metal (MLM) nanoplatform is designed for effective endosomal escape that facilitates intracellular drug delivery and enhanced anticancer therapy...
February 20, 2024: ACS Applied Materials & Interfaces
#10
JOURNAL ARTICLE
J S W Borgers, A W van Schijndel, J V van Thienen, S Klobuch, T T P Seijkens, R P Tobin, L van Heerebeek, A Driessen-Waaijer, M W Rohaan, J B A G Haanen
BACKGROUND: Treatment with tumor-infiltrating lymphocytes (TILs) is rapidly evolving for patients with solid tumors. Following metastasectomy, TILs (autologous, intratumoral CD4+ and CD8+ T cells with the potential to recognize tumor-associated antigens) are isolated and non-specifically expanded ex vivo in the presence of interleukin-2 (IL-2). Subsequently, the TILs are adoptively transferred to the patients after a preconditioning non-myeloablative, lymphodepleting chemotherapy regimen, followed by administration of high-dose (HD) IL-2...
February 2024: ESMO Open
#11
JOURNAL ARTICLE
Jingjing Fang, Chaolu Shi, Qin Huang, Lei Huang, Xinnian Wang, Biqing Yan
Acute respiratory distress syndrome (ARDS) is a life-threatening condition characterized by lung inflammation and high mortality rates. Lung cancer, specifically lung adenocarcinoma (LUAD), is a major cause of cancer-related deaths worldwide. Patients with LUAD, particularly those undergoing chemotherapy, are more likely to develop ARDS. ARDS inflicts major malfunctioning in the immune system. We suspected a certain shared pathogenic mechanism between these diseases. This study analyzed 503 LUAD patients from the TCGA-LUAD cohort as the training set, 85 LUAD cases from the GSE30219 cohort as the validation set, and 24 RNA-seq samples from ARDS mice model and control groups in the GSE2411 cohort...
February 14, 2024: Environmental Toxicology
#12
JOURNAL ARTICLE
Biagio Ricciuti, Giuseppe Lamberti, Sreekar R Puchala, Navin R Mahadevan, Jia-Ren Lin, Joao V Alessi, Alexander Chowdhury, Yvonne Y Li, Xinan Wang, Liam Spurr, Federica Pecci, Alessandro Di Federico, Deepti Venkatraman, Adriana P Barrichello, Malini Gandhi, Victor R Vaz, Andy J Pangilinan, Danielle Haradon, Elinton Lee, Hersh Gupta, Kathleen L Pfaff, Emma L Welsh, Mizuki Nishino, Andrew D Cherniack, Bruce E Johnson, Jason L Weirather, Ian D Dryg, Scott J Rodig, Lynette M Sholl, Peter Sorger, Sandro Santagata, Renato Umeton, Mark M Awad
PURPOSE: Although immune checkpoint inhibitors (ICI) have extended survival in patients with non-small-cell lung cancer (NSCLC), acquired resistance (AR) to ICI frequently develops after an initial benefit. However, the mechanisms of AR to ICI in NSCLC are largely unknown. METHODS: Comprehensive tumor genomic profiling, machine learning-based assessment of tumor-infiltrating lymphocytes, multiplexed immunofluorescence, and/or HLA-I immunohistochemistry (IHC) were performed on matched pre- and post-ICI tumor biopsies from patients with NSCLC treated with ICI at the Dana-Farber Cancer Institute who developed AR to ICI...
January 11, 2024: Journal of Clinical Oncology
#13
JOURNAL ARTICLE
Atsuto Mouri, Kyoichi Kaira, Ou Yamaguchi, Kosuke Hashimoto, Yu Miura, Ayako Shiono, Tomonori Kawasaki, Kunihiko Kobayashi, Hisao Imai, Hiroshi Kagamu
BACKGROUND: The relationship between antinuclear antibody (ANA) and the efficacy of programmed death-1 (PD-1) blockade remains controversial. Here, we investigated the prognostic significance of ANA titer in patients with non-small cell lung cancer (NSCLC) receiving pembrolizumab monotherapy as the first-line treatment, compared with that of platinum-based chemotherapy with PD-1 blockade. METHODS: Our clinical data based on the ANA titer (1:80) were retrospectively reviewed for patients with advanced NSCLC, who were treated with first-line pembrolizumab monotherapy and platinum-based chemotherapy with PD-1 blockade...
December 31, 2023: International Journal of Clinical Oncology
#14
JOURNAL ARTICLE
Lei Wang, Meng Diao, Zheng Zhang, Minlin Jiang, Shifu Chen, Deping Zhao, Zhenguo Liu, Caicun Zhou
OBJECTIVE: Lung cancer is classified into central and peripheral types based on the anatomic location. The present study aimed to explore the distinct patterns of genomic alterations between central- and peripheral-type non-small cell lung cancers (NSCLCs) with negative driver genes and identify potential driver genes and biomarkers to improve therapy strategies for NSCLC. METHODS: Whole-exome sequencing (WES) was performed with 182 tumor/control pairs of samples from 145 Chinese NSCLC patients without EGFR, ALK, or ROS1 alterations...
January 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
#15
JOURNAL ARTICLE
Yu Luo, Huiru Wang, Jian Zhong, Jianrong Shi, Xianlin Zhang, Yanni Yang, Ruixin Wu
BACKGROUND: APOBEC family play an important role in cancer mutagenesis and tumor development. The role of APOBEC family in lung adenocarcinoma (LUAD) has not been studied comprehensively. MATERIALS AND METHODS: The expression data of pan-cancer as well as LUAD was obtained from public databases. The expression level of APOBEC family genes was analyzed in different normal and cancer tissues. APOBEC mutagenesis enrichment score (AMES) was utilized to evaluate the APOBEC-induced mutations and the relation of APOBEC with genomic instability...
November 2023: Heliyon
#16
JOURNAL ARTICLE
Xiaohan Zhou, Liting You, Zhaodan Xin, Huiting Su, Juan Zhou, Ying Ma
BACKGROUND: Accumulating evidence supports the significant role of human microbiome in development and therapeutic response of tumors. Circulating microbial DNA is non-invasive and could show a general view of the microbiome of host, making it a promising biomarker for cancers. However, whether circulating microbiome is associated with prognosis of non-small cell lung cancer (NSCLC) and its potential mechanisms on tumor immune microenvironment still remains unknown. METHODS: The blood microbiome data and matching tumor RNA-seq data of TCGA NSCLC patients were obtained from Poore's study and UCSC Xena...
November 10, 2023: Journal of Translational Medicine
#17
JOURNAL ARTICLE
Lauren Holladay, Jennie Luu, Vyshnavy Balendra, Kevin Kmetz
BACKGROUND: Colorectal cancer (CRC) with subsequent bone metastasis is associated with a poor prognosis compared with patients who do not develop bone metastasis. However, metastasis in bone is rare, contrasted with more common locations such as the liver and lungs. As a result, the treatment methods targeting CRC bone lesions are limited. This review aims to compile information regarding current and potential medical and surgical treatment methods for colorectal cancer with specific regard to bone metastasis...
September 16, 2023: Cancer Treatment and Research Communications
#18
JOURNAL ARTICLE
X Shi, P Wang, Y Li, J Xu, J Yu, F Teng
PURPOSE/OBJECTIVE(S): Immune-checkpoint inhibitors (ICIs) combined with chemotherapy has been widely used in the first-line treatment of small cell lung cancer (SCLC) patients. However, the efficacy of ICIs for patients with brain metastases (BMs) of SCLC is limited. There are no effective factors to predict the efficacy. We developed and validate a model to predict intracranial efficacy for ICIs in patients with BMs from SCLC by using MRI radiomics. MATERIALS/METHODS: In this study, we collected 101 SCLC patients with BMs treated with ICIs...
October 1, 2023: International Journal of Radiation Oncology, Biology, Physics
#19
JOURNAL ARTICLE
Mouna Selmi, Abir Salek, Mahassen Barboura, Leila Njim, Amine Trabelsi, Aida Lahmar, Nolwenn Lautram, Emilie Roger, Tarek Baati, Leila Chekir Ghedira
Colorectal cancer (CRC) is the third most common worldwide. Depending on its stage, chemotherapy is usually given after surgery when CRC has already metastasized to other organs like the liver or lungs. Unfortunately, the current antineoplastics used for CRC therapies involve toxicity and side effects due to their lack of site-specificity. To overcome the drawbacks of heavy chemotherapy, this study proposes to assess the efficacy of thymoquinone (TQ), a bioactive constituent of black seeds ( Nigella sativa ), as an antiproliferative and pro-apoptotic agent on an experimental CRC model in mice...
September 26, 2023: Nanoscale advances
#20
JOURNAL ARTICLE
Ni Mao, Xiaobo Wu, Chaofeng Wang, Huijuan Mao, Jianzi Wei
PURPOSE: This study was developed to evaluate the effects of moxibustion on tumor microenvironmental hypoxia in a murine model of Lewis lung carcinoma (LLC). METHODS: Twenty-four tumor-bearing mice were randomized into tumor group (T), tumor + cisplatin group (TC), tumor + moxibustion group (TM), and tumor + cisplatin + moxibustion group (TMC) (n = 6/group). Six age-matched C57BL/6 mice were employed as control group (Ctrl)...
2023: Integrative Cancer Therapies
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
